Clinical trial
CONSENT - Comparison of metfOrmin XR to IR as moNotherapy in the Newly diagnoSed Type 2 diabEtes Patients for the gastroiNtestinal Tolerability and Efficacy: a Randomized, Parallel Control, Open-label and Multicenter Study
NCT02252965 is registered in ClinicalTrials.gov with Merck KGaA, Darmstadt, Germany as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- CONSENT - Comparison of metfOrmin XR to IR as moNotherapy in the Newly diagnoSed Type 2 diabEtes Patients for the gastroiNtestinal Tolerability and Efficacy: a Randomized, Parallel Control, Open-label and Multicenter Study
- Lead sponsor
- Merck KGaA, Darmstadt, Germany
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- December 31, 2014
- Completion date
- April 30, 2016
- Enrollment
- 532 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.